Combining radiation therapy with immunotherapy for liver cancer
A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma
PHASE1 · Abramson Cancer Center at Penn Medicine · NCT05488522
This study is testing a new treatment that combines radiation therapy with immunotherapy drugs to see if it can help people with advanced liver cancer who can't have surgery.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 18 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine (other) |
| Drugs / interventions | atezolizumab, bevacizumab |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05488522 on ClinicalTrials.gov |
What this trial studies
This phase I study investigates the safety and effectiveness of stereotactic body radiotherapy (SBRT) combined with the immunotherapy drugs atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma (HCC). The trial focuses on dose escalation to determine the optimal dosage and assess pharmacodynamic responses. Patients enrolled will receive repeated doses of SBRT alongside the immunotherapy agents to evaluate potential synergistic effects in treating HCC. The study aims to provide a new treatment option for patients whose cancer is not suitable for surgery or ablation.
Who should consider this trial
Good fit: Ideal candidates are patients with advanced hepatocellular carcinoma who are not eligible for curative surgery or ablation and require systemic therapy.
Not a fit: Patients with early-stage hepatocellular carcinoma who can undergo curative surgical or ablative treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could offer a novel treatment option that improves outcomes for patients with advanced liver cancer.
How similar studies have performed: While there is ongoing research in combining radiation with immunotherapy, this specific combination in advanced HCC is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated. Exclusion Criteria: \-
Where this trial is running
Philadelphia, Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Edgar Ben-Josef, MD — Abramson Cancer Center
- Study coordinator: Edgar Ben-Josef, MD
- Email: edgar.ben-josef@pennmedicine.upenn.edu
- Phone: 215-615-6767
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma